MP71-18 BLUE LIGHT CYSTOSCOPY VERSUS WHITE LIGHT CYSTOSCOPY FOR THE DETECTION OF BLADDER CANCER USING MODERN HD 4K EQUIPMENT: AN ANALYSIS OF PIVOTAL TRIAL AND REAL-WORLD DATA IN CHINA
Hanzhong Li,Hailong Hu,Jian Huang,Lulin Ma,Shudong Zhang,Jianming Guo,Xiuheng Liu,Yonglian Guo,Jin Wen,Hongxian Zhang,Shuai Jiang,Wang He,Cheng Liu,Xinli Kang,Fei Wang,Xiaoliang Yuan,Haefner Monika,Weber Bernd-Claus,Kristine Young-Halvorsen
DOI: https://doi.org/10.1097/01.ju.0001009548.76580.ba.18
2024-01-01
Abstract:You have accessJournal of UrologyBladder Cancer: Non-invasive IV (MP71)1 May 2024MP71-18 BLUE LIGHT CYSTOSCOPY VERSUS WHITE LIGHT CYSTOSCOPY FOR THE DETECTION OF BLADDER CANCER USING MODERN HD 4K EQUIPMENT: AN ANALYSIS OF PIVOTAL TRIAL AND REAL-WORLD DATA IN CHINA Hanzhong Li, Hailong Hu, Jian Huang, Lulin Ma, Shudong Zhang, Jianming Guo, Xiuheng Liu, Yonglian Guo, Jin Wen, Hongxian Zhang, Shuai Jiang, Wang He, Cheng Liu, Xinli Kang, Fei Wang, Xiaoliang Yuan, Haefner Monika, Weber Bernd-Claus, and Kristine Young-Halvorsen Hanzhong LiHanzhong Li , Hailong HuHailong Hu , Jian HuangJian Huang , Lulin MaLulin Ma , Shudong ZhangShudong Zhang , Jianming GuoJianming Guo , Xiuheng LiuXiuheng Liu , Yonglian GuoYonglian Guo , Jin WenJin Wen , Hongxian ZhangHongxian Zhang , Shuai JiangShuai Jiang , Wang HeWang He , Cheng LiuCheng Liu , Xinli KangXinli Kang , Fei WangFei Wang , Xiaoliang YuanXiaoliang Yuan , Haefner MonikaHaefner Monika , Weber Bernd-ClausWeber Bernd-Claus , and Kristine Young-HalvorsenKristine Young-Halvorsen View All Author Informationhttps://doi.org/10.1097/01.JU.0001009548.76580.ba.18AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Blue light cystoscopy (BLC) using hexaminolevulinate (HAL) is recommended to increase detection of non-muscle invasive bladder cancer (NMIBC) compared with white light cystoscopy (WLC) alone. However, the benefits of BLC with modern 4K LED equipment have not been assessed in a randomized controlled trial (RCT) in China. This pooled meta-analysis presents data from an RCT and a supporting real-world study (RWS) conducted in China. The aim of this study was to compare HAL BLC with WLC in the detection of bladder cancer using state of the art equipment. METHODS: In RCT (NCT05600322), patients (n=158) with known or suspected bladder cancer were enrolled in seven Chinese hospitals from November 2022 to June 2023. In the prospective RWS, additional patients (n=19) of the same inclusion criteria and measured for the same outcomes were enrolled at Hainan General Hospital from December 2022 to July 2023, and were included in the pooled analysis. Patients received intravesical HAL (Hexvix, Photocure ASA) and underwent WLC before BLC (System blue, Richard Wolf GmbH). The primary endpoint was the proportion of patients with histologically confirmed tumors (Ta, T1, or CIS) who have at least one such lesion found by BLC but not by WLC. Secondary endpoints included detection of CIS, lesion specific detection rate, false positive rates, adverse events (AEs), and satisfaction with device performance. RESULTS: A total of 177 patients were enrolled, with 128 patients included in the full analysis set. Among 109 patients with confirmed Ta, T1, or CIS, 46 patients (42.2%), had at least one confirmed lesion found by BLC but not by WLC (p<0.0001). Of 128 patients, 11.7% (15/128) of patients had CIS, of which 80% (12/15) CIS patients showed at least 1 additional confirmed CIS lesion found by BLC but not by WLC. Detection rates for CIS, Ta, T1 and T2-T4 tumors were 95.2%, 100%, 98.3% and 100% for BLC and 42.9%, 76.5%, 91.7% and 100% for WLC, respectively. The false-positive rate was 23.4% for BLC and 16.0% and WLC. 209 AEs occurred in 110 patients, all mild to moderate, of which 200 were classified as unrelated to HAL. No AEs were related to System blue. Overall satisfaction with device performance was reported as excellent (83.8%) and good (12.4%) (RCT). CONCLUSIONS: Data from the first RCT and supporting RWS conducted in China re-confirm the superiority of HAL BLC over WLC, using state-of-the-art HD 4K equipment, in detecting bladder cancer, especially CIS. HAL and System blue also demonstrate good tolerability. Source of Funding: N/A © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1168 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Hanzhong Li More articles by this author Hailong Hu More articles by this author Jian Huang More articles by this author Lulin Ma More articles by this author Shudong Zhang More articles by this author Jianming Guo More articles by this author Xiuheng Liu More articles by this author Yonglian Guo More articles by this author Jin Wen More articles by this author Hongxian Zhang More articles by this author Shuai Jiang More articles by this author Wang He More articles by this author Cheng Liu More articles by this author Xinli Kang More articles by this author Fei Wang More articles by this author Xiaoliang Yuan More articles by this author Haefner Monika More articles by this author Weber Bernd-Claus More articles by this author Kristine Young-Halvorsen More articles by this author Expand All Advertisement PDF downloadLoading ...